Clinical trials
Early Alzheimer's Disease clinical trials
Below are recruiting early alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT07221344RecruitingPhase 1/Phase 2
Study of an experimental drug for early Alzheimer's disease
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
East York, OntarioAges 18–80 - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07036328Recruiting
Magnetic brain stimulation to slow memory loss in Alzheimer's
This study tests whether a noninvasive magnetic brain stimulation treatment can slow down cognitive decline in people with early Alzheimer's disease. You'll receive daily sessions over several weeks, and the goal is to see if it helps preserve memory and thinking skills.
AmsterdamAges 50–85 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT06996730RecruitingPhase 2/Phase 3
Study of donanemab and RG6289 for genetic Alzheimer's disease
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
Medellín, AntioquiaAges 25–65 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT06741553Recruiting
Studying lecanemab for early Alzheimer's disease
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hangzhou, ZhejiangAges Up to 85 years - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06362707RecruitingPhase 2
Fasudil trial for early Alzheimer's disease
This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.
Tromsø, NordlandAges 50–100 - NCT06322667Recruiting
Study of lecanemab in early Alzheimer's disease
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
HiroshimaAges 18 years+ - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06080659Recruiting
Brain network study for Alzheimer's and Parkinson's
This study uses brain scans to look for patterns that might help diagnose memory or movement problems like Alzheimer's or Parkinson's disease. It compares people with mild symptoms, like forgetfulness or early Parkinson's, to healthy volunteers.
RennesAges 50–80 - NCT05924425RecruitingPhase 4
Daridorexant for insomnia in early memory decline
This trial tests whether daridorexant can improve sleep in people who have mild cognitive impairment or early Alzheimer’s disease and struggle with insomnia. It may help by improving how long and how well you sleep, with monitoring of sleep patterns and memory-related measures.
MontpellierAges 60–85
Hear when a new Early Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early alzheimer's disease?
- Yes. Clin2 currently lists 109 recruiting early alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.